(-0.05%) 5 097.27 points
(0.13%) 38 291 points
(-0.07%) 15 916 points
(-1.35%) $82.72
(6.08%) $2.04
(-0.03%) $2 346.40
(-0.23%) $27.47
(3.77%) $956.90
(-0.18%) $0.933
(-0.28%) $10.99
(-0.51%) $0.796
(1.73%) $93.46
-4.01% HKD 33.50
Live Chart Being Loaded With Signals
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases...
Stats | |
---|---|
Volumen de hoy | 1.40M |
Volumen promedio | 1.53M |
Capitalización de mercado | 9.34B |
EPS | HKD0 ( 2024-03-25 ) |
Próxima fecha de ganancias | ( HKD0 ) 2024-06-25 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -22.64 |
ATR14 | HKD0.0510 (0.15%) |
Volumen Correlación
Keymed Biosciences Inc. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Keymed Biosciences Inc. Correlación - Moneda/Commodity
Keymed Biosciences Inc. Finanzas
Annual | 2023 |
Ingresos: | HKD354.10M |
Beneficio Bruto: | HKD317.22M (89.59 %) |
EPS: | HKD-1.370 |
FY | 2023 |
Ingresos: | HKD354.10M |
Beneficio Bruto: | HKD317.22M (89.59 %) |
EPS: | HKD-1.370 |
FY | 2022 |
Ingresos: | HKD100.06M |
Beneficio Bruto: | HKD97.48M (97.42 %) |
EPS: | HKD-1.180 |
FY | 2021 |
Ingresos: | HKD110.27M |
Beneficio Bruto: | HKD93.07M (84.40 %) |
EPS: | HKD-14.34 |
Financial Reports:
No articles found.
Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico